Exclusive: Myeloid Therapeutics raises $73M, bringing in ARCH ahead of in vivo program entering the clinic
Myeloid Therapeutics has raised a $73 million Series A2 round that brings ARCH Venture Partners in as a new investor, as the biotech prepares to enter the clinic with its first in vivo mRNA program targeting myeloid cells.
Myeloid was started in 2019 to explore the idea of making drugs centered on myeloid cells, or the white blood cells that play a frontline role in the immune response.
Co-founded by the biochemist Ronald Vale and oncologist Siddhartha Mukherjee, among others, Myeloid is based on research showing these immune cells play a key role in certain types of tumors. Since publicly launching in January 2021 with a $50 million Series A round, the biotech now has 42 employees, CEO Daniel Getts told Endpoints News, with plans to grow to roughly 50 people over the next 12 months. Its drug candidate is already producing encouraging — albeit very early — clinical results.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
